Talk:Everolimus

This is the talk page for discussing improvements to the Everolimus article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Everolimus.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Please, I work with transplats persons I will receive more information about the best therapy, sirolimus or verlimus, and if you have a comparative study betwen these two medications.

Thanks This page is very helpfull. r2ro_99@yahoo.com

Xience

Should we move the stuff about Xience V into a new Xience V article ? If we do it would be easier to expand it without overwhelming this Everolimus article. Rod57 (talk) 00:46, 7 September 2008 (UTC)[reply]

Everolimus Structure

I believe that there is an error in the structure shown for everolimus. I believe that the methyl group on the ethylene bridge between the lactone and the cyclohexyl ring should be in the R configuration (solid wedge).

F. R. Green III (talk) 15:59, 24 December 2009 (UTC)[reply]

Yes, you're right. I'll correct the structure as soon as possible. Fvasconcellos (t·c) 16:10, 24 December 2009 (UTC)[reply]

Need more on Kidney cancer

Probably approved also in Europe for advanced renal cell carcinoma. Rod57 (talk) 20:20, 28 April 2011 (UTC)[reply]

Novartis investigating use as anti-aging drug

". . . Novartis has completed a successful pilot trial examining its cancer drug everolimus as a potential treatment to reverse immunosenescence, or the gradual deterioration of the immune system that occurs with age and is a major cause of disease and death."

http://www.voanews.com/content/reu-drugmakers-push-boundaries-old-age/2510089.html

(Similar content appeared in the Baltimore Sun for 11/13/2014 in an article headlined "Drugmakers look to push bounds of aging." Couldn't find that online 11/13; sometimes articles from the Sun are posted online a couple of days after their appearance in the hard-copy newspaper.)

Jo3sampl (talk) 13:32, 13 November 2014 (UTC)[reply]

Adverse reactions

They seem common and often serious so I've added a report from one trial but really it needs a more comprehensive summary eg from some reviews covering a wider range of trials and conditions. - Rod57 (talk) 00:41, 29 February 2016 (UTC)[reply]

Specification on typography

Just wished to enquire why some brand names are italicized and some bold. Zuke Denvar (talk) 04:19, 13 June 2019 (UTC)[reply]

The Anti-Aging feature of this drug deserves more recognition

It's a highly significant advancement in medicine, and can cause a 440% lifespan increase in mice and its suggested this is the case for humans too. doi:10.1007/s11357-020-00274-1 p1139. It should be the most significant part of the page in my opinion. It has attention from harvard medical school doi:10.1016/j.cmet.2014.01.001 and its recognised by the ageing institute. this is well worth having a vaccine style rollout with. 141.195.131.11 (talk) 03:18, 27 September 2023 (UTC)[reply]